Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 January 07, 2019 at 12:00 PM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 January 02, 2019 at 12:00 PM UTC
Internal link ProQR Therapeutics Announces Results for the Third Quarter of 2014 November 24, 2014 at 12:00 PM UTC
Internal link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares September 23, 2014 at 05:37 PM UTC